Hormone and cholesterol medicines for early womb lining cancer or precancer
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests whether medroxyprogesterone acetate (a progesterone hormone) plus atorvastatin (a cholesterol medicine) can treat early, limited problems in the womb lining—either atypical hyperplasia or early cancer (Grade 1) that has not spread into the muscle wall. It may help shrink or clear the abnormal tissue while supporting keeping fertility and the uterus.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed by hysteroscopy with either atypical endometrial hyperplasia (AEH) or early endometrial cancer Grade 1 with no spread into the womb muscle
- Your scans (MRI/CT/ultrasound with contrast, if used) show no suspicious spread outside the uterus
- You want to keep your uterus and future pregnancy potential (reproductive function)
- You can follow the study plan closely for treatment and follow-up visits
- You are not pregnant (and can’t become pregnant during the study)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests adding orlistat to standard hormone therapy for people with early endometrial cancer or atypical hyperplasia who have not fully responded to initial hormone treatment. It aims to preserve fertility and avoid hysterectomy.
This study looks at small lab samples taken from early endometrial cancer to see how sensitive the tumor is to progesterone treatment. It may help doctors choose the safest treatment that preserves fertility and the uterus for the right patients.
This trial tests whether adding GnRH medicine and letrozole to standard progestin treatment can better control early, low-risk endometrial cancer or atypical hyperplasia in people who are not obese. It may help some patients avoid progression while keeping the uterus, especially for those wanting future fertility.
This trial studies a weight-management approach plus a progesterone-releasing IUD (LNG-IUS) and megestrol to treat endometrial atypical hyperplasia, a high-risk precancer of the uterine lining. It may help shrink or control the abnormal cells while supporting fertility or keeping the uterus.
This trial tests a combination of two hormone-blocking drugs (GnRHa plus letrozole) for women with early-stage, obesity-related endometrial cancer who haven't responded well to standard hormone therapy alone. The goal is to preserve the uterus and fertility while controlling the cancer.
This study looks at whether a hormone-releasing IUD (LNG-IUS) can treat early-stage endometrial cancer or very early abnormal cell growth while helping you keep the option for future pregnancy. It aims to see how well the treatment works and how it affects fertility-related outcomes.
Hear when a new Atypical Endometrial Hyperplasia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.